Xueyi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xueyi Chen has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Sanjay K. Jain
Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
13 shared publications Medha Singh
Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
7 shared publicationsCarlos E. Ruiz-Gonzalez
Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
4 shared publications- Charles Arthur Peloquin
College of Pharmacy and Emerging Pathogens Institute, University of Florida , Gainesville, Florida
4 shared publications - Elizabeth W. Tucker
Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
4 shared publications Madelynn Shambles
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, USA
4 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 6178
Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models
- 21 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 6178
Open AccessHost-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models
- Open Access
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0019026
Ethionamide versus ethambutol-containing first-line regimens for TB meningitis
Ethionamide has emerged as an alternative to ethambutol for the treatment of tuberculous meningitis (TB meningitis). Here, we show that ethionamide- and ethambutol-containing first-line TB regimens achieved similar bactericidal activities in brain tissues and reduction in neuroinflammation in a mouse model of TB meningitis. However, ethionamide, but not ethambutol, achieves brain concentrations above the minimum inhibitory concentration for Mycobacterium tuberculosis .
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0019026
Open AccessEthionamide versus ethambutol-containing first-line regimens for TB meningitis
Ethionamide has emerged as an alternative to ethambutol for the treatment of tuberculous meningitis (TB meningitis). Here, we show that ethionamide- and ethambutol-containing first-line TB regimens achieved similar bactericidal activities in brain tissues and reduction in neuroinflammation in a mouse model of TB meningitis. However, ethionamide, but not ethambutol, achieves brain concentrations above the minimum inhibitory concentration for Mycobacterium tuberculosis .
- Open Access
- 8 March 2026
- Published by Springer Nature in Research Square
Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models
Tuberculous meningitis (TB meningitis) is a major cause of death and neurological deficit despite recommended antibiotic and corticosteroid treatments, primarily due to dysregulated neuroinflammation. Here, we investigate a diverse panel of 12 immunomodulatory drugs as host-directed treatments (HDTs) for TB meningitis utilizing a cross-species framework comprising studies in a mouse model of TB meningitis with clinical endpoints, and parallel mechanistic studies in a newly developed immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. We identify new HDTs that outperform the current standard of care by reducing mortality and neurological deficits in mice via suppression of neuroinflammation. Importantly, these HDTs significantly reduce microglial activation in Mycobacterium tuberculosis -infected human brain organoids and attenuate proinflammatory cytokines, particularly IFNγ within CD4 + T-cells in patient-derived PBMCs. These findings highlight the potential of targeted HDTs to improve outcomes in TB meningitis and warrant clinical investigation.
- 8 March 2026
- Published by Springer Nature in Research Square
Open AccessHost-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models
Tuberculous meningitis (TB meningitis) is a major cause of death and neurological deficit despite recommended antibiotic and corticosteroid treatments, primarily due to dysregulated neuroinflammation. Here, we investigate a diverse panel of 12 immunomodulatory drugs as host-directed treatments (HDTs) for TB meningitis utilizing a cross-species framework comprising studies in a mouse model of TB meningitis with clinical endpoints, and parallel mechanistic studies in a newly developed immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. We identify new HDTs that outperform the current standard of care by reducing mortality and neurological deficits in mice via suppression of neuroinflammation. Importantly, these HDTs significantly reduce microglial activation in Mycobacterium tuberculosis -infected human brain organoids and attenuate proinflammatory cytokines, particularly IFNγ within CD4 + T-cells in patient-derived PBMCs. These findings highlight the potential of targeted HDTs to improve outcomes in TB meningitis and warrant clinical investigation.
- Open Access
- 23 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , e195-e199
Addition of Clofazimine Enhances the Activity of Standard Treatment Regimen in a Mouse Model of Tuberculous Meningitis
Tuberculous meningitis causes substantial mortality due to limited penetration of antibiotics to the central nervous system and excessive neuroinflammation. This study evaluated clofazimine as an adjunct to the standard first-line tuberculosis regimen, in a mouse model. Mice were infected intracerebrally with Mycobacterium tuberculosis and treated for 6 weeks. Addition of clofazimine markedly reduced the brain bacterial burden, achieving measurable brain tissue concentrations despite minimal cerebrospinal fluid penetration, as well as attenuated brain tissue inflammation. These findings indicate that clofazimine enhances bactericidal activity of the standard regimen and mitigate neuroinflammation, supporting further investigation and clinical evaluation for tuberculous meningitis.
- 23 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , e195-e199
Open AccessAddition of Clofazimine Enhances the Activity of Standard Treatment Regimen in a Mouse Model of Tuberculous Meningitis
Tuberculous meningitis causes substantial mortality due to limited penetration of antibiotics to the central nervous system and excessive neuroinflammation. This study evaluated clofazimine as an adjunct to the standard first-line tuberculosis regimen, in a mouse model. Mice were infected intracerebrally with Mycobacterium tuberculosis and treated for 6 weeks. Addition of clofazimine markedly reduced the brain bacterial burden, achieving measurable brain tissue concentrations despite minimal cerebrospinal fluid penetration, as well as attenuated brain tissue inflammation. These findings indicate that clofazimine enhances bactericidal activity of the standard regimen and mitigate neuroinflammation, supporting further investigation and clinical evaluation for tuberculous meningitis.
- Open Access
- 10 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , e170-e179
Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for Tuberculous Meningitis
Tuberculous meningitis (TB meningitis), the most severe form of tuberculosis, carries high mortality and neurological sequelae, and current rifampin-based regimen are limited by poor central nervous system penetration. Alternative rifamycins like rifapentine and rifabutin, with different pharmacokinetic profiles, are effective for treating drug-susceptible pulmonary tuberculosis, with rifapentine now forming the basis of a World Health Organization-approved 4-month daily rifapentine-moxifloxacin regimen, and retrospective studies showing that rifabutin-based regimens are effective and well tolerated, however, both drugs still need dedicated evaluation in TB meningitis. Mice were intracranially inoculated with Mycobacterium tuberculosis and treated with rifamycin (rifampin, rifapentine, or rifabutin)-based regimens at human equipotent doses. We assessed the bactericidal activities of the 3 regimens, rifamycin tissue concentrations, brain inflammation (brain magnetic resonance imaging, tissue immunofluorescence, cytokines), and neuronal injury. Both rifapentine- and rifabutin-containing regimens demonstrated bactericidal activity in the brain, similar to or better than the standard rifampin-containing regimen, as well as reduced neuroinflammation and brain injury. Alternate rifamycins, rifapentine and rifabutin, show therapeutic activity and neuroprotective effects, supporting their evaluation in clinical trials for treating TB meningitis.
- 10 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , e170-e179
Open AccessBeyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for Tuberculous Meningitis
Tuberculous meningitis (TB meningitis), the most severe form of tuberculosis, carries high mortality and neurological sequelae, and current rifampin-based regimen are limited by poor central nervous system penetration. Alternative rifamycins like rifapentine and rifabutin, with different pharmacokinetic profiles, are effective for treating drug-susceptible pulmonary tuberculosis, with rifapentine now forming the basis of a World Health Organization-approved 4-month daily rifapentine-moxifloxacin regimen, and retrospective studies showing that rifabutin-based regimens are effective and well tolerated, however, both drugs still need dedicated evaluation in TB meningitis. Mice were intracranially inoculated with Mycobacterium tuberculosis and treated with rifamycin (rifampin, rifapentine, or rifabutin)-based regimens at human equipotent doses. We assessed the bactericidal activities of the 3 regimens, rifamycin tissue concentrations, brain inflammation (brain magnetic resonance imaging, tissue immunofluorescence, cytokines), and neuronal injury. Both rifapentine- and rifabutin-containing regimens demonstrated bactericidal activity in the brain, similar to or better than the standard rifampin-containing regimen, as well as reduced neuroinflammation and brain injury. Alternate rifamycins, rifapentine and rifabutin, show therapeutic activity and neuroprotective effects, supporting their evaluation in clinical trials for treating TB meningitis.
- Open Access
- 10 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
18F-Fluorodeoxysorbitol PET for noninvasive detection of invasive mold infections: preclinical and first-in-human studies
Invasive mold infections are a major cause of mortality in immunosuppressed and cancer patients. Diagnosis is challenging, requiring invasive procedures or reliance on fungal biomarkers with limited sensitivity and an inability to detect non-Aspergillus molds. Here, we perform whole-body 18F-fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET) in nine prospectively enrolled patients with high-suspicion of invasive mold infections (eventually confirmed using culture or molecular assays, n = 4) or other pathologies (n = 5) with localization of 18F-FDS PET signal to infection sites as the primary outcome (NCT05611892). 18F-FDS PET (120 or 180 min after injection), rapidly detects and localizes invasive pulmonary and cerebral infections due to Aspergillus, non-Aspergillus (galactomannan-negative), or azole-resistant molds, and differentiates them from sterile inflammation or cancer. Moreover, 18F-FDS selectively and rapidly accumulates intracellularly in a range of clinically relevant molds, including azole-resistant molds, via a saturable process. In animals, 18F-FDS PET is able to detect and localize pulmonary and cerebral aspergillosis, as well as rhinosinusal infections due to Aspergillus, Rhizopus, and Mucor, confirming the clinical data. 18F-FDS can be easily synthesized from 18F-fluorodeoxyglucose (18F-FDG), which is widely available, and represents a promising, noninvasive diagnostic tool for detecting, localizing and monitoring of invasive mold infections throughout the body.
- 10 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open Access18F-Fluorodeoxysorbitol PET for noninvasive detection of invasive mold infections: preclinical and first-in-human studies
Invasive mold infections are a major cause of mortality in immunosuppressed and cancer patients. Diagnosis is challenging, requiring invasive procedures or reliance on fungal biomarkers with limited sensitivity and an inability to detect non-Aspergillus molds. Here, we perform whole-body 18F-fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET) in nine prospectively enrolled patients with high-suspicion of invasive mold infections (eventually confirmed using culture or molecular assays, n = 4) or other pathologies (n = 5) with localization of 18F-FDS PET signal to infection sites as the primary outcome (NCT05611892). 18F-FDS PET (120 or 180 min after injection), rapidly detects and localizes invasive pulmonary and cerebral infections due to Aspergillus, non-Aspergillus (galactomannan-negative), or azole-resistant molds, and differentiates them from sterile inflammation or cancer. Moreover, 18F-FDS selectively and rapidly accumulates intracellularly in a range of clinically relevant molds, including azole-resistant molds, via a saturable process. In animals, 18F-FDS PET is able to detect and localize pulmonary and cerebral aspergillosis, as well as rhinosinusal infections due to Aspergillus, Rhizopus, and Mucor, confirming the clinical data. 18F-FDS can be easily synthesized from 18F-fluorodeoxyglucose (18F-FDG), which is widely available, and represents a promising, noninvasive diagnostic tool for detecting, localizing and monitoring of invasive mold infections throughout the body.
- 12 June 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (7) , 2009-2017
Improved Radiosynthesis of [18F]-Labeled Oxazolidinone Antibiotics for Future Clinical Translation
The development of radiolabeled antibiotics for positron emission tomography/computed tomography (PET/CT) imaging has the potential to substantially improve our ability to measure compartment-specific antibiotic exposures for various infections. This study focuses on the radiosynthesis and optimization of fluorine-18 [18F]-labeled oxazolidinone antibiotics, specifically [18F]linezolid and [18F]sutezolid, followed by in vivo imaging of the latter. Copper-mediated radiofluorination of boronated precursors was enhanced by variation of the phase-transfer catalysts and base conditions to improve the reaction efficiency. Preclinical evaluation of [18F]sutezolid in uninfected and Mycobacterium tuberculosis-infected mice demonstrated favorable biodistribution and metabolic stability, with minimal defluorination. Dynamic PET imaging confirmed rapid clearance, predominant renal and hepatobiliary excretion, and consistent tissue uptake across infected and uninfected models. These findings support the feasibility of [18F]-labeled oxazolidinones as PET tracers for compartment-specific antibiotic exposures, paving the way for optimizing antibiotic dosing and future personalized treatments in patients.
- 12 June 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (7) , 2009-2017
Improved Radiosynthesis of [18F]-Labeled Oxazolidinone Antibiotics for Future Clinical Translation
The development of radiolabeled antibiotics for positron emission tomography/computed tomography (PET/CT) imaging has the potential to substantially improve our ability to measure compartment-specific antibiotic exposures for various infections. This study focuses on the radiosynthesis and optimization of fluorine-18 [18F]-labeled oxazolidinone antibiotics, specifically [18F]linezolid and [18F]sutezolid, followed by in vivo imaging of the latter. Copper-mediated radiofluorination of boronated precursors was enhanced by variation of the phase-transfer catalysts and base conditions to improve the reaction efficiency. Preclinical evaluation of [18F]sutezolid in uninfected and Mycobacterium tuberculosis-infected mice demonstrated favorable biodistribution and metabolic stability, with minimal defluorination. Dynamic PET imaging confirmed rapid clearance, predominant renal and hepatobiliary excretion, and consistent tissue uptake across infected and uninfected models. These findings support the feasibility of [18F]-labeled oxazolidinones as PET tracers for compartment-specific antibiotic exposures, paving the way for optimizing antibiotic dosing and future personalized treatments in patients.
- Open Access
- 27 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue necrosis, fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68+ and CD11b+ cells. Finally, positron emission tomography (PET) in live animals using clinically translatable biomarkers for apoptosis (18F-ICMT-11) and fibrosis (18F-FAPI-74), demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed in postmortem analysis. Our studies suggest that proapoptotic drugs such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis and may be protective against post-TB lung disease.
- 27 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Open AccessProapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue necrosis, fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68+ and CD11b+ cells. Finally, positron emission tomography (PET) in live animals using clinically translatable biomarkers for apoptosis (18F-ICMT-11) and fibrosis (18F-FAPI-74), demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed in postmortem analysis. Our studies suggest that proapoptotic drugs such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis and may be protective against post-TB lung disease.
- Open Access
- 2 October 2024
- Published by Springer Nature in Research Square
18F-Fluorodeoxysorbitol PET for Noninvasive Detection of Invasive Mold Infections in Patients
Invasive mold infections are a major cause of mortality in immunosuppressed and cancer patients. Diagnosis is challenging, requiring invasive procedures or reliance on fungal biomarkers with limited sensitivity and an inability to detect non-Aspergillus molds. Here, we perform whole-body 18F-fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET) and computed tomography (CT) in nine prospectively enrolled patients with high-suspicion of invasive mold infections (eventually confirmed using culture or molecular assays) or other pathologies (NCT05611892). 18F-FDS PET/CT is safe and can rapidly detect and localize invasive pulmonary and cerebral infections due to Aspergillus, non-Aspergillus (galactomannan-negative), or azole-resistant (Aspergillus calidoustus) molds, and differentiate them from sterile inflammation or cancer. Moreover, 18F-FDS selectively and rapidly accumulates intracellularly in a wide range of clinically relevant molds, including azole-resistant molds, via a saturable process. Tissue histology from eight patients with invasive mold infections demonstrates that lesional biomass occupied by molds is ~50-fold higher than for bacterial infections. In animals, 18F-FDS PET/CT is able to detect and localize pulmonary and cerebral aspergillosis, as well as rhinosinusal infections due to Aspergillus, Rhizopus, and Mucor, confirming the clinical data. 18F-FDS PET represents a promising, noninvasive diagnostic tool for the detection and localization of invasive mold infections throughout the body.
- 2 October 2024
- Published by Springer Nature in Research Square
Open Access18F-Fluorodeoxysorbitol PET for Noninvasive Detection of Invasive Mold Infections in Patients
Invasive mold infections are a major cause of mortality in immunosuppressed and cancer patients. Diagnosis is challenging, requiring invasive procedures or reliance on fungal biomarkers with limited sensitivity and an inability to detect non-Aspergillus molds. Here, we perform whole-body 18F-fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET) and computed tomography (CT) in nine prospectively enrolled patients with high-suspicion of invasive mold infections (eventually confirmed using culture or molecular assays) or other pathologies (NCT05611892). 18F-FDS PET/CT is safe and can rapidly detect and localize invasive pulmonary and cerebral infections due to Aspergillus, non-Aspergillus (galactomannan-negative), or azole-resistant (Aspergillus calidoustus) molds, and differentiate them from sterile inflammation or cancer. Moreover, 18F-FDS selectively and rapidly accumulates intracellularly in a wide range of clinically relevant molds, including azole-resistant molds, via a saturable process. Tissue histology from eight patients with invasive mold infections demonstrates that lesional biomass occupied by molds is ~50-fold higher than for bacterial infections. In animals, 18F-FDS PET/CT is able to detect and localize pulmonary and cerebral aspergillosis, as well as rhinosinusal infections due to Aspergillus, Rhizopus, and Mucor, confirming the clinical data. 18F-FDS PET represents a promising, noninvasive diagnostic tool for the detection and localization of invasive mold infections throughout the body.
- Open Access
- 14 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.
- 14 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessDynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.